Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of subcutaneous fixed-dose pertuzumab + trastuzumab versus intravenous pertuzumab + trastuzumab with chemotherapy in HER2-positive early breast cancer
2017-004897-32Phase 3Unknown
- Sponsor
- Roche
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pertuzumab and trastuzumab in breast cancer (2 arms), sponsored by Roche. Primary endpoint: Serum pertuzumab trough concentration. Status: unknown.
02
Drugs
pertuzumabtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2017-004897-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004897-32.